Lupin surges on entering into licensing agreement with Alvion

06 Apr 2022 Evaluate

Lupin is currently trading at Rs. 780.20, up by 2.20 points or 0.28% from its previous closing of Rs. 778.00 on the BSE.

The scrip opened at Rs. 772.00 and has touched a high and low of Rs. 786.00 and Rs. 771.50 respectively. So far 21341 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 798.90 and Rs. 736.35 respectively. The current market cap of the company is Rs. 35614.93 crore.

The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.

Lupin has entered into a licensing agreement with Alvion Pharmaceuticals P.C. (Alvion) to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.

The company is committed to providing new affordable treatment options to healthcare providers and patients. By commercializing cardiometabolic drugs in the Southeast Asian region, the company will play a significant role in improving the quality of healthcare and access to medicines.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2184.00 26.65 (1.24%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.